Changshan Pharmaceutical’s Nadroparin Calcium Injection Obtains Belarus Drug Registration Certificate
May 22, 2025
Source: drugdu
80
On May 20, Changshan Pharmaceutical(300255) announced that the company's drug Nadroparin Calcium Injection has obtained the drug registration certificate issued by the Belarusian drug administration department.
Nadroparin calcium injection is an injection with specifications of 0.4ml and 0.6ml. This drug is mainly used to treat moderate or high-risk venous thrombosis, prevent venous thromboembolic diseases, treat established deep vein thrombosis, and be used in combination with aspirin to treat unstable angina and acute stage of non-Q wave myocardial infarction; and prevent blood clot formation in extracorporeal circulation during hemodialysis.
In the first quarter of 2025, Changshan Pharmaceutical achieved revenue of 259 million yuan and net profit attributable to shareholders of the parent company of 3.78 million yuan.
https://finance.eastmoney.com/a/202505203409519560.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Which Strength Training Method Is Best for You? Experts Break Down the Options July 9, 2025
- Is One Type of Water Healthier Than Another? Here’s What Experts Say July 9, 2025
- Innovent Biologics’ Suvicitamab is approved for marketing, solving the dilemma in the treatment of platinum-resistant ovarian cancer July 7, 2025
- Everest Medicines’ Next-Generation BTK Inhibitor EVER001 Announces Latest Clinical Results, Continues to Demonstrate Efficacy and Safety July 7, 2025
- Jinsai Pharmaceutical’s Fuxin Qibaimab was approved, reducing the risk of gout recurrence by 87% in half a year July 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
